Henao-Piedrahita N

Language: Spanish
References: 36
Page: 18-29
PDF size: 255.57 Kb.

ABSTRACT

Thrombotic microangiopathy is a syndrome characterized by a formation of microthrombi in the circulation leading to microangiopathic hemolytic anemia and thrombocytopenia with multiorgan failure due to tissue ischemia. It generates a great mortality and can be produced by inherited or acquired causes. The thrombotic microangiopathies are disorders that require timely diagnosis and treatment to reduce morbidity and mortality in patients who suffer from them. This paper describes the main characteristics of the three most important primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura, Shiga toxin-mediated hemolytic uremic syndrome and complement mediated thrombotic microangiopathy.

REFERENCES

1. Moake JL. Thrombotic microangiopathies. N Engl J Med [Internet] 2002; 347 (8): 589-600. DOI: 10.1056/NEJMra020528.

2. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med [Internet] 2014; 371 (7): 654-66. DOI: 10.1056/NEJMra1312353.

3. Tsai H-M. Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome. Hematol Oncol Clin North Am 2013; 27 (3): 565-84. doi. 10.1016/j. hoc.2013.02.006.

4. George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) [Internet]. 2011; 25 (10): 908-14.

5. George JN, Nester CM. Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA). Uptodate 2019 23.

6. Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol 2014; 92 (2): 156-63. doi. 10.1111/ ejh.12222.

7. Bendapudi PK, Hurwitz S, Fry A, Marques MB, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol [Internet] 2017; 4 (4): e157-64. doi. 10.1016/S2352-3026(17)30026-1.

8. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116 (20): 4060-9. doi. 10.1182/blood-2010-07-271445.

9. Kremer-Hovinga JA, Coppo P, Lämmle B, Moake JL, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Prim 2017; 3 (1): 17020. doi. 10.1038/nrdp.2017.20.

10. Reese JA, Muthurajah DS, Hovinga JAK, Vesely SK, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60 (10): 1676-82. doi. 10.1002/pbc.24612.

11. Terrell DR, Vesely SK, Hovinga JAK, Lämmle B, et al. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol 2010; 85 (11): 844-7. doi. 10.1002/ ajh.21833.

12. Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol 2015; 22 (5): 452-9. doi. 10.1097/MOH.0000000000000169.

13. Furlan M, Robles R, Galbusera M, Remuzzi G, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. N Engl J Med 1998; 339 (22): 1578-84. doi. 10.1056/ NEJM199811263392202.

14. Scully M, Blombery P. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 2014; 15. doi. 10.2147/JBM.S46458.

15. Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am 2014; 32 (3): 649-71. doi. 10.1016/j.emc.2014.04.008.

16. Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR, et al. First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? Blood 2010; 116 (21): 1427. https://doi.org/10.1182/blood. V116.21.1427.1427.

17. Furlan M, Robles R, Morselli B, Sandoz P, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (1): 8-13.

18. Gasser C, Gautier E, Steck A, Siebenmann RE, et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 1955;85 (38-39): 905-9.

19. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365 (9464): 1073-86. doi. 10.1016/S0140- 6736(05)71144-2.

20. Witham PK, Yamashiro CT, Livak KJ, Batt CA. A PCR-based assay for the detection of Escherichia coli Shiga-like toxin genes in ground beef. Appl Environ Microbiol 1996; 62 (4): 1347-53. doi. 10.1128/AEM.62.4.1347-1353.1996.

21. Bell BP, Goldoft M, Griffin PM, Davis MA, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272 (17): 1349-53.

22. Buchholz U, Bernard H, Werber D, Böhmer MM, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365 (19): 1763-70. DOI: 10.1056/NEJMoa1106482.

23. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16 (4): 1035-50. doi. 10.1681/ ASN.2004100861.

24. Karpac CA, Li X, Terrell DR, Kremer-Hovinga JA, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141 (5): 696-707. doi. 10.1111/j.1365-2141.2008.07116.x.

25. Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, et al. Typical and atypical hemolytic uremic syndrome in the critically ill. Crit Care Clin 2020; 36 (2): 333-56. doi. 10.1016/j.ccc.2019.11.004.

26. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017; 390 (10095): 681-96. doi. 10.1016/S0140-6736(17)30062-4.

27. Garg AX, Suri RS, Barrowman N, Rehman F, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome. JAMA 2003; 290 (10): 1360. doi. 10.1001/ jama.290.10.1360.

28. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148 (1): 37-47. doi. 10.1111/j.1365- 2141.2009.07916.x.

29. Geerdink LM, Westra D, van Wijk JAE, Dorresteijn EM, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27 (8): 1283-91. doi. 10.1007/s00467-012- 2131-y.

30. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, et al. Complement factor H–related protein 1 deficiency and factor h antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013; 8 (3): 407- 15. doi. 10.2215/CJN.01260212.

31. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry 2013; 52 (23): 3949-62. https://doi.org/10.1021/bi4003452.

32. Noris M, Caprioli J, Bresin E, Mossali C, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5 (10): 1844-59. doi. 10.2215/CJN.02210310.

33. Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey M-A, Macher M-A, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18 (8): 2392- 400. doi. 10.1681/ASN.2006080811.

34. Goodship THJ, Cook HT, Fakhouri F, Fervenza FC, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91 (3): 539-51. doi. 10.1016/j.kint.2016.10.005.

35. Cataland SR, Holers VM, Geyer S, Yang S, et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014; 123 (24): 3733-8. doi. 10.1182/blood-2013-12-547067.

36. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Engl J Med [Internet]. 2009; 361 (17): 1676-87. doi. 10.1056/NEJMra0902814.